Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 8/20 | 0.56 |
| ▸ | STAT6 | P42226 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 2/20 | 0.47 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCND2 | P30279 | 1/20 | 0.45 |
| ▸ | CCND3 | P30281 | 1/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413320 | 0.92 | IGF1R (0.52) | IGF1RSTAT6MAPK8AURKAEGFR | |
| SCHEMBL4422225 | 0.90 | CDK4 (0.52) | STAT6AURKAEGFRFGFR1SRC | |
| SCHEMBL3865248 | 0.89 | CCND3 (0.52) | IGF1RSTAT6MAPK8AURKAPLK4 | |
| SCHEMBL4418799 | 0.88 | IGF1R (0.49) | IGF1RSTAT6MAPK8AURKAEGFR | |
| SCHEMBL3865121 | 0.87 | STAT6 (0.53) | IGF1RSTAT6MAPK8AURKAPKMYT1 | |
| SCHEMBL14600274 | 0.86 | GSK3B (0.48) | IGF1RMAPK8AURKACDK4CCND1 | |
| SCHEMBL4418794 | 0.85 | IGF1R (0.45) | IGF1REGFRPLK4PKMYT1SLC2A1 | |
| SCHEMBL4415197 | 0.85 | IGF1R (0.54) | IGF1RSTAT6PLK4PKMYT1PDGFRB | |
| SCHEMBL5583941 | 0.84 | SRC (0.63) | IGF1RSTAT6MAPK8AURKAEGFR | |
| SCHEMBL5565424 | 0.83 | MARK3 (0.46) | IGF1RSTAT6MAPK8AURKAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615921-B1 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-03-18 | — | — | EP | claimed |
| US-7163941-B2 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-01-16 | — | — | US | claimed |
| EP-1615921-A2 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | claimed |
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (DE) | 2005-06-16 | — | — | US | claimed |
| WO-2004085436-A2 | PYRIDO[2,3-D]PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| EP-1615921-B1 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-7163941-B2 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1615921-A2 | PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (DE) | 2005-06-16 | — | — | US | disclosed |
| WO-2004085436-A2 | PYRIDO[2,3-D]PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | IGF1R 2397/4885STAT6 3057/4885MAPK8 971/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | IGF1R 1649/4885STAT6 2273/4885MAPK8 1470/4885 |
| US-20050130984-A1 | Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | LCK, TYRO3, ABL1 | IGF1R 1562/4885STAT6 527/4885MAPK8 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.